In a groundbreaking development for dementia care in Singapore, the country's first regulated clinical trial of lymphatic bypass surgery for Alzheimer's disease is yielding encouraging early results. Known as the Cervical Lymphatico-Venous Bypass for Alzheimer's Disease (CLyVeB-AD-1) trial, this innovative procedure at Changi General Hospital (CGH) targets the brain's waste clearance system to potentially slow cognitive decline and alleviate associated anxiety.
Alzheimer's disease affects an estimated 70,000 of the roughly 100,000 Singaporeans living with dementia, making local research efforts crucial. This trial represents a shift from pharmaceutical approaches to surgical intervention, repurposing a technique traditionally used for lymphedema to address glymphatic dysfunction—a key factor in Alzheimer's pathology.
Understanding the Glymphatic System and Its Role in Alzheimer's
The glymphatic system, short for glial-lymphatic, is the brain's primary waste removal mechanism. Unlike the rest of the body, which relies on the lymphatic system to drain protein-rich fluid, the brain lacks traditional lymph vessels. Instead, cerebrospinal fluid (CSF) flows through perivascular spaces around blood vessels, facilitated by glial cells, to flush out metabolic waste, including amyloid-beta and tau proteins that accumulate in Alzheimer's disease (AD).
This clearance peaks during deep non-rapid eye movement (NREM) sleep, when brain cells shrink slightly to widen fluid channels. In AD patients, glymphatic flow diminishes due to aging, vascular issues, or protein buildup, leading to neuroinflammation, synaptic loss, and cognitive impairment. Disruptions are evident via MRI diffusion tensor imaging along perivascular spaces (DTI-ALPS), showing reduced flow correlating with disease severity.
Singaporean researchers, building on global findings, hypothesize that enhancing meningeal and cervical lymphatic drainage could compensate for glymphatic failure. The deep cervical lymphatic vessels in the neck serve as the brain's outflow pathway, making them an ideal surgical target.
The Lymphaticovenous Anastomosis Procedure: Step-by-Step
Lymphaticovenous anastomosis (LVA), or deep cervical lymph node to venous bypass (DCLNV-BP), is a microsurgical technique. Performed under general anesthesia, it lasts 1-2 hours bilaterally.
- Preparation: Preoperative imaging (MRI, PET, lymphoscintigraphy) confirms glymphatic impairment and suitable anatomy.
- Incision: Small 2-3 cm incisions in the neck expose deep cervical lymph nodes (levels II-III).
- Anastomosis: Using supermicrosurgery (magnification >20x, 11-0 sutures), surgeons connect 1-2 lymph nodes or vessels to adjacent veins (e.g., internal jugular), creating low-resistance bypasses.
- Confirmation: Indocyanine green (ICG) lymphography verifies immediate flow.
- Closure: Wounds heal in 7-10 days; patients resume normal activities in weeks.
Originally for limb lymphedema post-cancer, LVA boasts high patency rates (90%+ at 1 year). In AD, it aims to boost CSF-lymph outflow, reducing neurotoxins.
CLyVeB-AD-1 Trial Design and Patient Cohort
Prospectively registered as NCT06965062 on ClinicalTrials.gov, this proof-of-concept, single-arm, open-label study at CGH targets 10 patients but has treated four to date (women, 61-73 years, mild-moderate AD confirmed by biomarkers/PET).
Eligibility: MMSE 18-26, CDR 1, amyloid/tau positive, no contraindications. Primary outcomes: cognitive (MMSE, MoCA), functional (ADL), behavioral changes at 6/12/24 months. Secondary: CSF biomarkers, MRI/PET, anxiety/depression scales (GDS, NPI-Q). Safety monitored via adverse events.
Principal investigator Clinical Assistant Professor Vincent Tay (CGH Plastic Surgery) trained in Hangzhou, China—pioneers of DCLNV-BP—with co-investigators Jeremy Sun (plastic surgery head) and Lim Si Ching (geriatrics).
Promising Early Results: Cognition, Anxiety, and Beyond
At six months post-January 2025 surgeries, all four patients showed stability or gains. CSF analysis revealed reduced amyloid/tau levels; neuroimaging confirmed glymphatic enhancement.
- Cognitive: MMSE/MoCA scores improved 2-4 points, signaling better memory/recall.
- Anxiety/Behavior: One patient's longstanding anxiety/depression eased (GDS drop); another regained language/social skills.
- Functional: Caregivers noted cheerfulness, story recall, daily task independence.
Family feedback: "She recalls past stories gradually improving." No serious adverse events; minor swelling resolved.
Photo by CFPhotosin Photography on Unsplash
Patient Perspectives and Real-World Impact
Though anonymized, anecdotes highlight hope. A 65-year-old's mood lifted, reducing caregiver burden. Another's interactivity boosted family bonds. These align with Chinese pilots (e.g., Xie et al., 200+ cases: MMSE stabilization P=0.022).View trial on ClinicalTrials.gov
In Singapore's aging society (1 in 10 over 60 has dementia), such interventions could transform care, complementing drugs like lecanemab (approved 2025).
Contributions from Singapore's Higher Education Institutions
Duke-NUS Medical School led a seminal review (PubMed 40794118) proposing LVA for AD, authored by Yu-Hsin Yen et al., advocating RCTs with DTI-ALPS/CSF metrics. Collaborators from National Neuroscience Institute (NNI) and SGH underscore interdisciplinary academia-hospital synergy.
NTU and NUS glymphatic studies (e.g., early AD markers) provide foundational data. This trial exemplifies translational research, fostering careers in neurosurgery, geriatrics, and biomedical engineering.
For aspiring researchers, Singapore's ecosystem offers grants via NMRC/A*STAR, positions at Duke-NUS.Read Duke-NUS review
Comparing to Existing Alzheimer's Therapies
LVA differs from anti-amyloid monoclonals (lecanemab: 27% slower decline, but ARIA risks, infusions). It's one-time, minimally invasive vs. ongoing drugs/devices (e.g., Yale/Monash neck stimulators).
| Treatment | Mechanism | Efficacy | Risks |
|---|---|---|---|
| LVA | Enhance drainage | Prelim cognitive/mood gains | Surgical (low) |
| Lecanemab | Amyloid clearance | Modest slowing | Brain edema/swelling |
| Cholinesterase inhibitors | Symptom relief | Temporary | GI side effects |
Challenges, Risks, and Ethical Considerations
Limitations: Small n=4, no controls yet; long-term patency unknown. Risks: Infection, thrombosis (<5% in lymphedema LVA). Ethical: Target early AD for best outcomes; informed consent stresses experimental status.
Global skepticism (ALZFORUM: placebo?) necessitates Phase II/III RCTs.CNA full report
Future Directions and Broader Implications
CGH plans 6 more recruits 2026, expanding to 60+ sites. Integration with drugs/stimulators possible. For Singapore higher ed, boosts neuro research hubs at Duke-NUS/NTU.
Actionable: Clinicians monitor via biomarkers; researchers pursue grants. Patients/caregivers explore trials via HSA.
Photo by Matt Boitor on Unsplash
Career Opportunities in Singapore's Alzheimer's Research
This trial highlights demand for experts in microsurgery, neuroimaging, biomarkers. Duke-NUS seeks postdocs; CGH/NNI faculty roles abound. Singapore's RIE2025 invests S$25B in health research.
